Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

Image: AstraZeneca says Calquence, obinutuzumab combo met primary endpoint in phase 3 ELEVATE-TN trial. Photo: courtesy of Astrazeneca.